Trial Evaluating Safety, Tolerability and Immune Response of AG-707
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, multi-center, sequential, dose-escalating study of three dose cohorts
of AG-707. Individuals who meet all of the inclusion and exclusion criteria for eligibility
will be randomized to receive either AG-707 (at the 80 µg dose), AG-707 with QS-21 (at the 80
µg dose), placebo, or QS-21. Each patient will be monitored for safety as specified in the
protocol.